Viracta Therapeutics, Inc. (VIRX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Viracta Therapeutics, Inc. (VIRX) trades at $0.01. Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for virus-associated malignancies. Market cap: $388,698, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for VIRX: VIRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VIRX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VIRX: 1/1 perspectives are bearish.
How is this calculated? →Viracta Therapeutics, Inc. (VIRX) Healthcare & Pipeline Overview
Viracta Therapeutics, Inc. is a precision oncology company specializing in the development of therapies for virus-associated malignancies, with a focus on Epstein-Barr virus-positive cancers. Their lead candidate, Nana-val, is currently in Phase II trials, positioning them in a competitive biotechnology landscape focused on targeted cancer treatments.
What Is the Investment Thesis for VIRX?
Viracta Therapeutics operates in the high-growth oncology market, specifically targeting virus-associated malignancies. The company's lead candidate, Nana-val, is in Phase II trials, representing a potential near-term catalyst. Successful trial outcomes could drive significant value appreciation. Viracta's focus on EBV+ cancers addresses a specific unmet need, offering a targeted approach to treatment. However, the company's small market capitalization ($0.00B) and reliance on clinical trial success present significant risks. The company's P/E ratio is -0.01. Continued progress in clinical development and strategic collaborations are crucial for realizing the company's potential. The company's beta is 0.28.
Based on FMP financials and quantitative analysis
VIRX Key Highlights
- Lead product candidate Nana-val is in Phase II clinical trials for Epstein-Barr virus-positive lymphoma, targeting a specific unmet need in oncology.
- Development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor, offering potential for expansion into new therapeutic areas.
- Focus on virus-associated malignancies provides a targeted approach to cancer treatment, differentiating Viracta from competitors.
- Actively exploring development and collaboration opportunities for vecabrutinib and VRx-510, potentially expanding the company's pipeline and market reach.
- Rebranded from Sunesis Pharmaceuticals in 2021 to reflect a sharpened focus on precision oncology and virus-associated cancers.
Who Are VIRX's Competitors?
VIRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $23.12 | +4.69% | $2.05B | 79 |
| ANAB AnaptysBio, Inc. | $67.29 | +8.00% | $2.90B | 79 |
| CGEN Compugen Ltd. | $2.38 | +1.06% | $225.51M | 76 |
| ABCL AbCellera Biologics Inc. | $7.69 | -2.29% | $2.35B | 76 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.29 | -0.70% | $3.20B | 68 |
| ZYME Zymeworks Inc. | $26.61 | +5.05% | $1.96B | 68 |
| IVBXF Innovent Biologics, Inc. | $10.15 | -13.05% | $17.61B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIRX's Key Strengths?
- Targeted approach to virus-associated malignancies.
- Lead product candidate in Phase II clinical trials.
- Experienced management team with expertise in oncology drug development.
- Pipeline of preclinical and clinical-stage assets.
What Are VIRX's Weaknesses?
- Limited financial resources and reliance on external funding.
- High risk associated with clinical trial outcomes.
- Small market capitalization and limited trading volume.
- Dependence on the success of a few key drug candidates.
What Could Drive VIRX Stock Higher?
- Data readout from Phase II clinical trial of Nana-val in EBV+ lymphoma.
- Announcement of strategic collaborations or partnerships for vecabrutinib or VRx-510.
- Initiation of clinical trials for VRx-510.
- Enrollment and progress in ongoing clinical trials.
- Continued research and development efforts to expand the pipeline.
What Are the Key Risks for VIRX?
- Financial-distress signal — its Altman Z-Score of -25.19 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Unfavorable clinical trial results for Nana-val or other pipeline assets.
- Regulatory hurdles and delays in drug approvals.
- Competition from larger pharmaceutical companies with greater resources.
- Limited financial resources and reliance on external funding.
- Risks associated with investing in OTC stocks, including limited liquidity and transparency.
What Are the Growth Opportunities for VIRX?
- Expansion of Nana-val into additional EBV+ malignancies: Viracta has the opportunity to expand the use of Nana-val beyond lymphoma to other EBV+ cancers, such as nasopharyngeal carcinoma and other solid tumors. The global nasopharyngeal carcinoma market is projected to reach $1.9 billion by 2027, representing a significant growth opportunity. This expansion is contingent on successful clinical trial results and regulatory approvals, with potential timelines extending over the next 3-5 years.
- Development of vecabrutinib in combination with CAR-T cell therapies: Combining vecabrutinib with CAR-T cell therapies could enhance the efficacy of CAR-T treatments in certain hematological malignancies. The CAR-T cell therapy market is expected to reach $10.7 billion by 2028. Viracta's ability to secure partnerships and demonstrate clinical synergy will be critical for success in this area, with potential collaborations and trial initiations within the next 2-3 years.
- Advancement of VRx-510 into clinical trials: Progressing VRx-510, a preclinical-stage PDK-1 inhibitor, into clinical trials represents another growth opportunity. PDK-1 inhibition has potential in various oncology indications, providing optionality for Viracta. The timeline for this advancement is dependent on preclinical data and regulatory approvals, with potential for Phase 1 trials within the next 2-3 years.
- Strategic collaborations and partnerships: Viracta can leverage strategic collaborations and partnerships to accelerate the development and commercialization of its pipeline assets. Partnering with larger pharmaceutical companies could provide access to funding, expertise, and distribution networks. The success of these collaborations will depend on the attractiveness of Viracta's assets and the ability to negotiate favorable terms, with potential partnership announcements in the next 1-2 years.
- Geographic expansion into new markets: While currently focused on the US market, Viracta has the potential to expand its reach into other geographic regions, particularly those with a higher prevalence of EBV+ cancers, such as Asia. This expansion would require significant investment in clinical trials and regulatory approvals in these regions, with potential market entry within the next 3-5 years.
What Opportunities Does VIRX Have?
- Expansion into new therapeutic areas and indications.
- Strategic collaborations and partnerships with larger pharmaceutical companies.
- Advancement of pipeline assets into clinical trials.
- Geographic expansion into new markets.
What Threats Does VIRX Face?
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and potential delays in drug approvals.
- Unfavorable clinical trial results.
- Changes in the healthcare landscape and reimbursement policies.
What Are VIRX's Competitive Advantages?
- Proprietary drug candidates targeting specific virus-associated malignancies.
- Clinical trial data demonstrating the safety and efficacy of its therapies.
- Intellectual property protection for its drug candidates and technologies.
What Does VIRX Do?
Viracta Therapeutics, Inc., formerly known as Sunesis Pharmaceuticals, Inc., was incorporated in 1998 and rebranded in February 2021 to reflect its sharpened focus on virus-associated malignancies. Headquartered in Cardiff-by-the-Sea, California, the company operates as a precision oncology entity dedicated to developing innovative drugs for treating cancers linked to viral infections. Viracta's lead product candidate, Nana-val, combines nanatinostat and valganciclovir and is currently undergoing Phase II clinical trials for Epstein-Barr virus-positive lymphoma. Additionally, the company is conducting an open-label Phase 2 basket trial for relapsed/refractory EBV+ lymphoma and a Phase 1b/2 trial for EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Beyond Nana-val, Viracta's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor, and VRx-510, a preclinical-stage PDK-1 inhibitor. The company is actively exploring development and collaboration opportunities for these assets, including combinations with CAR-T cell therapies for vecabrutinib and various oncology indications for VRx-510. With a team of 26 employees, Viracta is committed to advancing its pipeline and addressing unmet needs in the treatment of virus-associated cancers.
What Products and Services Does VIRX Offer?
- Develop drugs for the treatment of virus-associated malignancies.
- Focus on precision oncology to target specific cancer types.
- Advance Nana-val through clinical trials for Epstein-Barr virus-positive lymphoma.
- Develop vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor.
- Develop VRx-510, a preclinical-stage PDK-1 inhibitor.
- Evaluate development and collaboration opportunities for its pipeline assets.
- Conduct clinical trials to assess the safety and efficacy of its drug candidates.
How Does VIRX Make Money?
- Develop and commercialize novel therapies for virus-associated malignancies.
- Generate revenue through potential partnerships, licensing agreements, and eventual product sales.
- Focus on research and development to advance its pipeline of drug candidates.
What Industry Does VIRX Operate In?
The biotechnology industry is characterized by intense competition and high R&D costs. Viracta Therapeutics operates within the oncology segment, specifically targeting virus-associated malignancies. This niche focus allows for a more targeted approach but also carries the risk of limited market size. The overall oncology market is experiencing substantial growth, driven by an aging population and advancements in personalized medicine. Key trends include the development of targeted therapies and immunotherapies. Competitors are focusing on broader oncology indications, while Viracta is carving out a space in virus-associated cancers.
Who Are VIRX's Key Customers?
- Patients with virus-associated malignancies, particularly Epstein-Barr virus-positive lymphoma.
- Oncologists and hematologists who treat these patients.
- Hospitals and cancer centers that provide cancer care.
Net buyingInsider Activity
The most recent 12 insider filings for Viracta Therapeutics, Inc. break down as 4 sales and 8 purchases. On net that is roughly 200K shares acquired (about $114K) — insiders putting money in tends to read as conviction.
VIRX Valuation & Market Position
With a 389K market cap, Viracta Therapeutics, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on assets is -90.1%, showing how much profit it generates from its asset base. A current ratio of 1.43 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
Viracta Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -25.19 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Viracta Therapeutics, Inc. revenue of about $37.6M for fiscal 2026, with EPS near $-0.64.
Company Profile
Viracta Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cardiff-by-the-Sea, US. The company is led by CEO Craig R. Jalbert. VIRX has traded publicly since 2005.
VIRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Viracta's upcoming clinical trials, indicating a belief in potential positive outcomes.
- Community sentiment has shifted positively as discussions around innovative treatments for viral infections gain traction.
- The company’s recent partnerships with research institutions highlight a commitment to advancing their therapeutic pipeline, fostering optimism.
- Increased media coverage on the need for effective antiviral therapies has raised awareness and interest in Viracta's mission.
Bear Case
- Concerns about the competitive landscape in antiviral treatments could overshadow Viracta's unique offerings, leading to skepticism.
- Recent social media discussions reflect uncertainty regarding the timeline for clinical trial results, which may dampen enthusiasm.
- Some investors are wary of the company's previous financial performance, raising doubts about its sustainability and growth potential.
- The overall market sentiment towards biotech stocks has been cautious, influenced by broader economic factors and regulatory challenges.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VIRX Latest News
No recent news available for VIRX.
VIRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VIRX.
Price Targets
Wall Street price target analysis for VIRX.
VIRX MoonshotScore
What does this score mean?
The MoonshotScore rates VIRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Craig R. Jalbert
CEO
Craig R. Jalbert serves as the CEO of Viracta Therapeutics, bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in various companies focused on oncology drug development. Jalbert's expertise spans strategic planning, business development, and clinical operations. He has a proven track record of driving growth and innovation in the healthcare sector. His leadership is pivotal in guiding Viracta's strategic direction and advancing its pipeline of novel therapies for virus-associated malignancies.
Track Record: Since assuming the role of CEO, Craig R. Jalbert has overseen the advancement of Nana-val into Phase II clinical trials and has spearheaded efforts to expand the company's pipeline through strategic collaborations and partnerships. He has also been instrumental in securing funding to support the company's research and development activities. Jalbert's leadership has been focused on driving clinical execution and building a strong foundation for future growth.
VIRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Viracta Therapeutics may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting and loss of investment.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and compliance with securities laws.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Research the company's history, including any past legal or regulatory issues.
- Company's focus on precision oncology and virus-associated malignancies.
- Advancement of Nana-val into Phase II clinical trials.
- Experienced management team with expertise in oncology drug development.
- Rebranding from Sunesis Pharmaceuticals to Viracta Therapeutics to reflect a sharper focus.
- Exploration of development and collaboration opportunities for its pipeline assets.
Viracta Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does Viracta Therapeutics, Inc. do?
Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for the treatment of virus-associated malignancies. Its lead product candidate, Nana-val, is in Phase II clinical trials for Epstein-Barr virus-positive lymphoma. The company also has a pipeline of preclinical and clinical-stage assets, including vecabrutinib and VRx-510. Viracta aims to address unmet needs in the treatment of cancers linked to viral infections through targeted therapies and strategic collaborations.
What are the main risks for VIRX?
The main risks for Viracta Therapeutics, Inc. include the inherent uncertainties associated with clinical trial outcomes, particularly for its lead product candidate, Nana-val. Regulatory hurdles and potential delays in drug approvals also pose significant risks. Competition from larger pharmaceutical companies with greater resources and established market presence is another key concern. Additionally, the company's limited financial resources and reliance on external funding create financial risks. Investing in OTC stocks carries additional risks, including limited liquidity and transparency.
What are the key factors to evaluate for VIRX?
Evaluate VIRX on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does VIRX data refresh on this page?
VIRX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VIRX's recent stock price performance?
Viracta Therapeutics, Inc. (VIRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted approach to virus-associated malignancies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VIRX overvalued or undervalued right now?
Valuing Viracta Therapeutics, Inc. (VIRX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VIRX?
Before investing in Viracta Therapeutics, Inc. (VIRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VIRX to a portfolio?
Key strength of Viracta Therapeutics, Inc. (VIRX): Targeted approach to virus-associated malignancies. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis pending for VIRX stock.